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Abstract: The objective of present investigation was to prepare and evaluate a pulsatile 
drugdelivery system of metoprolol tartrate. The prepared pulsatile delivery system consists of 
two different parts: a core tablet, containing the active ingredient, an erodible . The rapid 
release core tablet (RRCT) was prepared by using superdisintegrants along with active 
ingredient metoprolol tartrate. press coating of optimized RRCT was done by using different 
ratios of hydroxy propyl methyl cellulose (HPMC K100) and ethyl cellulose 5Cps. Developed 
formulations were evaluated for their physical characteristics, in vitro disintegration time and 
in vitro drug release profile (lag time).On the basis of these evaluation parameters it was found 
that optimized  pulsatile release formulation (P3F3)  showed time of 2hrs and  in-vitro drug 
relrease time of 8hrs with97.8%released drug. The P3F3 formulation showed compliance with 
chronotherapeutic objective of hypertension. 
Keywords: Pulsatile drug delivery, Metoprolol tartrate, rapid release core tablet, press coating, 
lag time 
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INTRODUCTION 
Conventional controlled release drug 
delivery systems are based on single or 
multiple – unit reservoir or matrix system, 
which are designed to provide constant 
drug levels over an extended period of 
time. However, pulsatile delivery is 
desirable for drugs acting locally or having 
an absorption window in the gastro-
intestinal tract or for drugs with an 
extensive first pass metabolism, which 
develop biological tolerance, where the 
constant presence of the drug at the site of 
action diminishes the therapeutic effect, or 
for drugs with special the pharmacokinetic 
features designed according to the 
circadian rhythm of human. A pulsatile 
release profile is characterized by a lag time 
followed by rapid and complete drug 
release. Pulsatile drug delivery systems are 
generally classified into time - controlled 
and site - specific delivery system 1-4. 
The goal of chronotherapeutics is to 
synchronize the timing of treatment with 
the intrinsic timing of illness. Unlike 
homeostatic formulations, which provide 
relatively constant plasma drug levels over 
24 hours. 5The release from the time 
controlled delivery is primarily controlled by 
the system, while the release from the 
sitespecific group is primary controlled by 
the biological environment in the gastro-
intestinal tract such as pH of the site of 
action or enzymes.Most pulsatile drug 
delivery systems are reservoir devices 
covered with a barrier coating. The barrier 
can dissolve, erode or rupture during/after 
a certain lag time, after which the drug is 
released rapidly from the inner reservoir. 
The rupturing of the barriers is induced by 
an expanding core upon water penetration 
through the barrier coating. The expansion 
can be caused by effervescent excipient or 
swelling agents.6,7 
 Metoprolol tartrate is a cardioselective 
beta-adrenergic blocking agent used in 
hypertension, cardiac arrhythmias, angina 
pectoris, heart failure, hyperthyroidism and 
prophylactic, in the treatment of migraine. 
Metoprolol, with its incomplete 
bioavailability (due to first-pass 
metabolism), short halflife (4-6 h), multiple 
daily dosing, and high aqueous solubility is 
an ideal candidate for the pulsatile release 
system for improving patient compliance.8,9 
The present study focuses on the 
development of pulsatile release tablets of 
Metaprolol Tartrate at a peroral, time - 
controlled single-unit dosage form. The 
proposed system consists of a core tablet 
coated with two layers, an inner swelling 
layer and an outer rupturable coating.  
The swelling layer is composed of 
croscarmellose sodium, a super disintegrant 
and Micro crystalline celllose (MCC) as a 
diluent, while the rupturable coating is an 
ethyl cellulose.10,11 
MATERIALS AND METHODS: 
MATERIALS:  
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Metaprolol Tartrate (Chandra labs), MCC 
(Degussa India Pvt. Ltd., Mumbai L.R) , Cross 
povidone, Sodium starch glycolate (S.D. Fine 
Chem. Ltd., Mumbai L.R),  HPMC K100, 
Ethyl cellulose 5Cps(L.R. Sisco Research 
Lab.Pvt. Mumbai). All materials used were 
of analytical grade.  
METHOD: 
Formulation of core tablets by direct 
compression: 
The inner  core tablets  were  prepared by 
using direct compression method as shown  
in  Table.No.1. powder mixtures  of 
metaprolol tartrate ,  microcrystalline 
cellulose  (MCC, Avicel  PH-102), cross-
carmellose sodium (Ac-Di-Sol) ,SSG, 
crospovidone, lactulose monohydrate  
ingredients were dry blended for  20  min.  
followed by addition of Magnesium 
Stearate. The  mixtures were then  further 
blended for 10 min., 150mg of resultant 
powder blend was manually compressed 
using KBr hydraulic press at a pressure of 1 
ton, with a 9mm punch and die to obtain 
the core tablet. 
Formulation of mixed blend for barrier 
layer: 
 The various formulation compositions 
containing Ethylcellulose and HPMC.   
Different compositions were weighed dry 
blended at about 10 min. and used as press-
coating material to prepare press-coated 
pulsatile tablets  respectively by direct 
compression method. 
Preparation of press-coated tablets: 
The core tablets were press-coated with  
250 mg of mixed blend as given in 
Table.No.2 125mg of barrier layer material 
was weighed and transferred into a 13mm 
die then the core tablet was placed 
manually at the center. The remaining 
125mg of the barrier layer materiel was 
added into the die and compressed at a 
pressure of 5 tons for 3min using KBr 
hydraulic press.12 
        Table.No.1. Formulation of Metoprolol Tartrate core tablets  
 



















Metoprolol 25 25 25 25 25 25 25 25 25 
Micro Crystalline Cellulose 118 126.5 125 118 126.5 125 118 126.5 125 
Crospovidone 3 4.5 6 - - - - - - 
Cross Carmellose Sodium - - - 3 4.5 6 - - - 
Sodium Starch Glycollate - - - - - - 3 4.5 6 
Magnesium Stearate 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 
Total Weight 150 150 150 150 150 150 150 150 150 
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Table.No.2: Formulation of Press Coat tablets using different percent ratios of HPMC K100& 
EC 5 Cps mixed blends  
Press coat P1 P2 P3 P4 P5 
HPMC K 100(%)  1 0 1 3 1 
E.C 5 Cps (%) 0 1 1 1 3 
Total wt of 
tablet(mg) 
400 400 400 400 400 
 
EVALUATION OF PRESS COATED TABLETS 
Evaluation of  rapid  release  core  (RRCT)  
and  press-coated tablets of  metaprolol 
tartrate sodium. 
Weight variation13 :  
Twenty tablets were randomly selected 
from each batch weighed individually. The 
average weight  and standard deviation was 
calculated.  
Thickness:   
Three tablets from each batch of 
formulation  were  collected  and  the  
thicknesses  of  the  tablets  were measured  
with  the  help  of  Vernier  caliper.  The 
average thickness was calculated.  
 Hardness : 
Hardness was measured using Monsanto 
tablet hardness tester. The hardness of five 
tablets in each batch was measured and the 
average hardness was calculated in terms of  
kg/cm2 .  
Friability (F)14:   
Friability  of the tablet determined using  
Roche friabilator. Pre-weighted sample of 
tablets were placed in the friabilator and 
were subjected to the 100 revolutions. 
Tablets were dusted using a soft muslin 
cloth and reweighed.  
 Wetting time :   
Wetting time of dosage form is related to  
the contact angle. A piece of tissue paper 
folded twice was placed in a small petridish 
containing 6 ml of water. Tablet was kept 
on the paper and the time for complete 
wetting was measured.   
Disintegration  time for  RRCTs :  
LABINDIA  DT  1000 USP disintegration test 
apparatus. To test the disintegration time of 
tablets, one tablet was placed in each tube 
and the basket  rack  was  positioned  in  a  
1  liter  beaker  containing phosphate buffer 
pH 6.8 at 37°C ± 1°C such that the tablet 
remains 2.5 cm below the surface of the 
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liquid. The time taken for the complete 
disintegration of the tablets was noted.  
In-vitro release studies for RRCTs  
Tablet was introduced into the basket of 
the LABINDIA TS 8000 USP dissolution test 
apparatus and the apparatus was set in 
motion at 50 rpm for time period of 1 hr, 5 
ml of sample was withdrawn for every 
15min  intervals and replaced by pH 7.2 
phosphate buffer solutions. Samples 
withdrawn were analyzed by UV 
spectrophotometer for presence of drug 
using buffer solution as blank at 342 nm.  
In-vitro Dissolution methods for press-
coated tablets :  
In –vitro Dissolution  studies  of  Pulsatile  
delivery  systems  was done with  the 
conventional paddle method at 37  ± 0.5 °C 
using 0.5% w/v  aqueous solution sodium 
lauryl sulfate in USP-II dissolution apparatus 
at 50 rpm. 5 ml of filtered aliquot was 
manually withdrawn at pre-determined 
time intervals and replaced with 5 ml of 
fresh 0.5% sodium lauryl sulfate solution 
maintained at the same temperature. The 
samples were analysed at 342nm using a 
UV spectrophotometer. The lag time and 
percentage release was  determined of the 
each formulation. 
 Release Kinetics15,16 : 
As a model-dependent approach, the 
dissolution data was fitted to four popular 
release models such as zero-order, first-
order, Higuchi and Peppa’s- Korsemeyer 
equations. The order of drug release from 
matrix systems was described by using zero 
order kinetics or first orders kinetics. The 
mechanism of drug release from the matrix 
systems was studied by using Higuchi 
equation and Peppa’s- Korsemeyer 
equation. The results are given in Table 
                                                                   
Q = kot   (zero order release kinetics)  
In (1-Q) = - K1t   (First order release kinetics) 
Q=K2t½    (Higuchi equation) 
 Mt/M = K.tn  Peppa’s and Korsemeyer 
equation (Power Law) 
Where Q   is the amount of drug released at 
time t, K0= zero order rate constant, K1= first 
order rate constant, K2= Higuchi rate 
constant,Mt is the amount of drug released 
at time t and M is the amount released at 
time , thus the Mt/M is the fraction of 
drug released at time t, k is the kinetic 
constant and n is the diffusion exponent. 
Stability Studies17 :  
Stability studies of the optimised 
formulation  of press coated tablets of 
Metaprolol tartrate were carried out to 
determine the effect of formulation 
additives on the stability of the drug and 
also to determine the physical stability of 
the formulation according to ICH guide 
lines. The  studies were carried out at 
25oC/60%RH, 30 ºC/65% RH and 40 ºC/75% 
RH for 90 days by storing the samples in 
stability chamber (Lab-care, Mumbai).  
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RESULTS &DISCUSSION 
 Pulsatile press coated tablets of Metoprolol 
tartrate were developed to prolong the 
gastric residence time and to increase the 
drug bioavailability. Metoprolol tartrate 
was chosen as a model drug because it is 
better absorbed in the stomach than the 
lower gastro intestinal tract. 
Drug-excipient compatibility: 
IR spectra for drug and optimised  
formulation(Figure.No.1&2) revealed that  
there was no incompatibility between drug 
and excipients because of no change in the 
wave numbers of functional groups of 
metoprolol tartrate 
 
Figure.No.1: FTIR Studies of the pure drug 
 
Figure.No.2: FTIR Studies of the optimized formulation 
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Post compressional parameters of core 
tablets: 
Weight variation, Thickness, Hardness, 
Friability, Disintegration time and wetting 
time: 
The values of weight variation, thickness, 
hardness, friability and assay of the twenty 
tablets  
(Table.No.3) were found to be within the 
limits of conventional oral tablets stated in 
the Indian Pharmacopoeia (IP, 1996). The 
average mass ranged from 1.18 to 1.62 %, 
thickness of the tablets varied from 2 mm 
to 2.5 mm, hardness of the tablets was in 
the range 4 to 4.5 kg/cm2, the friability 
ranged from 0.52 to 0.7%. disintegration 
time 1.5min to 4minand wetting time 46 to 
59 sec. The mass, thickness, hardness, 
friability, and disintegration time of all 
compressed tablets were within the limits 
as per USP. 
 















F1 1.65 4.5 2.5 0.7 4min 59Sec 
F2 1.57 4.2 2.3 0.55 3.5min 56Sec 
F3 1.42 4 2.4 0.62 1.5min 46 Sec 
F4 1.54 4.1 2.2 0.52 2min 49 Sec 
F5 1.18 4.3 2.4 0.62 2.12min 50 Sec 
F6 1.35 4.4 2 0.57 2.2min 51Sec 
F7 1.44 4.2 2.3 0.55 2.45min 55 Sec 
F8 1.23 4.3 2.4 0.62 2.2min 51 Sec 
F9 1.48 4.4 2 0.52 2.3min 54 Sec 
 
In-Vitro release studies of RRCT: 
In-Vitro release studies of rapid release core 
tablets (Figure.No.3) revealed that the 
formulation F3 showed faster dissolution 
rate with 97.8% drug release at the end of 
60 th min. This can be explained by 
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comparing with wetting time of F3. Here 
the super disintegrant Cross Povidone 
possess more capillary action for water 
absorption when compared to Cross 




Fig.No.3: Comparative dissolution profile of Metaprolol Tratrate tablets containing different 
concentrations of super disintegrants(F1-F9) 
Post compressional parameters of 
Metoprolol Tartrate press coated tablets 
The post compressional 
parameters(Tale.No.4) of Metaprolol 
tartrate press-coated pulsatile tablets(PF1 
to PF5) prepared by using different polymer 
ratios(HPMC K100:EC) also satisfied the 
compendial requirements. 










P1F3 1.65 6.5 6.5 0.7 
P2F3 1.57 6.7 6.45 0.55 
P3F3 1.42 6.6 6.4 0.62 
P4F3 1.3 7.2 6 0.54 
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In-vitro release studies of press coated 
tablets: 
In-vitro release profiles of press coated 
pulsatile tablets (Figure.No.4) of Metaprolol 
Tartrate revealed  that P3F3 formulation 
showed (96.3% ) best release at the end of 
8th hr. Here the composiion of coat  consists 
of  HPMC K100,(responsible for swellability) 
and ethyl Cellulose( responsible for 
erodabilility). The lag time of the system 
could be modified by several factors such as 
core composition& composition of swelling 
layer and rupturable layer. 
 
 
Fig.No.4: Comparative dissolution profile of Metaprolol Tratrate press coated tablets 
containing different concentrations of  ethyl cellulose and HPMC(P1F3 – P5F3). 
Release kinetics: 
Release kinetics of Metoprolol (Table.No.5) 
from the optimized formulation P3F3  was 
found to follow First order kinetics 
(correlation coefficient, r2 value 
0.981).Higuchi plot showed an r2 valve of 
0.986 for formulationP3 F3 suggesting that 
the diffusion plays an important role in the 
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Table.No.5: Release kinetics: Coefficient of correlation (r) values of   different batches of   
Metoprolol tartrate press coated tablets 
    Formulation     Zero order          First order       Higuchi’s           Peppa’s 
P1F3 0.976 0.870 0.929 0.934 
P2F3 0.975 0.915 0.954 0.971 
P3F3 0.979 0.981 0.986 0.994 
P4F3 0.971 0.990 0.994 0.995 
P5F3 0.983 0.923 0.957 0.966 
 
Stability studies: 
Stability studies(Table.No.6) of the  
optimised formulation  P3F3  showed that 
there was no significant change in the 
physical property and percent of drug 
release. 
Table.No.6: Stability studies of optimized formulation 
Sampling interval %  of  drug  release  during  8 hours 
25 0C/60%RH 30 0C/65% RH 40 0 C/75% RH 
0th Days 92 92 92 
15thDays 91.5 91.45 91.40 
45thDays 90.96 90.85 90.82 
90thDays 90.45 90.42 90.38 
 
CONCLUSION 
A once-daily time-controlled release 
pulsatile tablet of Metoprolol Ttartrate 
having short halflife was found to exert a 
satisfactory time-controlled release profiles 
which may provide an increased 
therapeutic efficacy.  
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